Home » Authors » Jim Shrine

Articles by Jim Shrine

Cephalon Acquiring Approved Muscle Relaxant For $100M

Aug. 24, 2007

Cephalon Acquiring Approved Muscle Relaxant For $100M

Aug. 24, 2007

Nuvelo Restarts Testing With Higher Dose Of Alfimerprase

Aug. 23, 2007

Nuvelo Restarts Testing With Higher Dose Of Alfimerprase

Aug. 23, 2007

Oncoscience Starts Phase III Trials Of YM's Nimotuzumab

Aug. 22, 2007

Oncoscience Starts Phase III Trials Of YM's Nimotuzumab

Aug. 22, 2007

Insys Registers For IPO To Fund Cannabinoid, Fentanyl Products

Aug. 21, 2007

Insys Registers For IPO To Fund Cannabinoid, Fentanyl Products

Aug. 21, 2007

Cephalon Planning sNDA Filing Of Fentora In Breakthrough Pain

Aug. 17, 2007

Cephalon Planning sNDA Filing Of Fentora In Breakthrough Pain

Aug. 17, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 12, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
KITE-753, a rapid manufactured CAR T therapy with superior antitumor efficacy and enhanced expansion in vivo
BioWorld Science
In a presentation at the recent American Society of Hematology meeting in San Diego, Kite Pharma Inc. reported preclinical data for KITE-753, an autologous rapid...
Keros stock wilts as it halts two dosing arms in hypertension study
BioWorld
After Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study in pulmonary arterial hypertension, the company’s stock crumpled after...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.